UPC issues first decision on second medical use

Court of First Instance rules on Sanofi v Amgen antibodies dispute | Claims dismissed as “unfounded” and lacking in evidence | All parties ordered to pay costs totalling €45m ($50m).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Unified Patent Court

Does the UPC offer a fresh take on patent validity?

5 September 2024 A distinctive UPC approach to patent validity and revocations is emerging as the court shows its willingness to break new ground, say Emily Bottle and Sebastian Moore of HSF.

Unified Patent Court

Sanofi and Regeneron triumph in UPC decision against Amgen

16 July 2024 UPC’s Munich Central Division revokes Amgen's patent | Decision stems from a revocation action initiated by Sanofi last year | Court's ruling focused on interpretations of patent claims and principles of inventive step.

More features

IP agencies vital to pharma and biotech grind to a halt

USPTO trims workforce amid govt shutdown crisis

How impactful is the new USPTO director’s S101 decision?

Global vaccine patents rise, as data reveals shift in Big Pharma strategy

Philips wins unprecedented trade secret sanctions against Chinese defendants

Womble Bond Dickinson partners jump to rival firm

EPO ruling clarifies appeal rights, blocking third-party intervention

Biotech sues AstraZeneca and Cellectis over mRNA patents

UPC issues first decision on second medical use

More on this story

Editor's picks

Editor's picks

More features